Natera reported a roughly 39% jump in preliminary Q4 revenue driven by Signatera MRD test volume, processing 225,300 MRD tests in the quarter and forecasting $2.3 billion revenue for 2025. Adaptive Biotechnologies said Q4 revenue rose ~51% and full‑year 2025 revenue rose 55%, led by strong ClonoSeq MRD demand and record consumables sales. Both companies cited volume growth in oncology molecular diagnostics and MRD platforms as the driver of revenue gains. The results reflect expanding clinical adoption of blood‑based MRD assays and genomic services; investors and payers will monitor reimbursement developments and evidence generation that underpin sustained commercial scaling.